Search Results - "Maroto, J.P."

OC-08: Phase I Trial of Sorafenib and Radiation: Acute Toxicity Report for a New Conservative Approach in Bladder Cancer by Ferrer Gonzalez, F, Sancho, G, Rovirosa, A, Maroto, J.P, Mellado, B, Vigues, F, Palou, J, Ribal, M.J, Boladeras, A, Garcia del Muro, X

Get full text

Recommendations on the management of controversies in advanced castrate-resistant prostate cancer by Cózar, J.M, Solsona, E, Morote, J, Miñana, B, Maroto, J.P, del Alba, A. González, Climent, M.Á, Carles, J, Alcaraz, A, Castellano, D

“…Abstract Context Controversies and uncertainties among integral management of advanced castration resistant prostate cancer continue to exist despite the…”
Get full text

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) by Rosenberg, J.E., Milowsky, M., Ramamurthy, C., Mar, N., McKay, R.R., Friedlander, T., Ferrario, C., Bracarda, S., George, S., Moon, H., Geynisman, D., Petrylak, D.P., Borchiellini, D., Burgess, E.F., Rey, J.P. Maroto, Carret, A-S., Yu, Y., Guseva, M.V., Moreno, B. Homet, O'Donnell, P.H.

Get full text

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy by de Bono, J.S., Molife, L.R., Sonpavde, G., Maroto, J.P., Calvo, E., Cartwright, T.H., Loesch, D.M., Feit, K., Das, A., Zang, E.A., Wanders, J., Agoulnik, S., Petrylak, D.P.

“…Treatment options remain limited for patients with castration-resistant prostate cancer (CRPC). We evaluated eribulin mesylate (E7389), a nontaxane…”
Get full text

The prostate cancer registry: Patient characteristics, treatments and preliminary outcomes from a large observational study of metastatic castration-resistant prostate cancer (mCRPC) by Chowdhury, S., Birtle, A.J., Bjartell, A., Costa, L.A.M., Feyerabend, S., Galli, L., Kalinka-Warzocha, E., Kramer, G., Rey, J.P. Maroto, Lumen, N., Matveev, V.B., Paiss, T., Spaeth, D., Antoni, L., Klumper, E., Wapenaar, R., Lee, E.

Get full text

Open-Label Phase II Trial of First-Line Everolimus Monotherapy in Patients with Advanced Papillary Renal Cell Carcinoma: Raptor Interim Analysis by Escudier, B., Bracarda, S., Maroto, J.P., Szczylik, C., Nathan, P., Negrier, S., Slimane, K., May, C., Porta, C., Grünwald, V.

Get full text

94 A REAL-LIFE COMPARATIVE EFFECTIVENESS SIMULATION OF PROGRESSION FREE SURVIVAL COMPARING FIRST-LINE SUNITINIB VS. BEVACIZUMAB + INTERFERON-ALPHA 2A IN METASTATIC RENAL CELL CARCINOMA-CONSIDERING THE EFFECTS OF DOWN-DOSING AND PATIENT COMPLIANCE by Mickisch, G.H, Schwander, B, Escudier, B, Bellmunt, J, Maroto, J.P, Porta, C, Walzer, S, Nuijten, M

Get full text

1091 PAIN OUTCOMES IN PATIENTS WITH BONE METASTASES FROM CASTRATE-RESISTANT PROSTATE CANCER: RESULTS FROM A PHASE 3 TRIAL OF DENOSUMAB VS. ZOLEDRONIC ACID by Brown, J.E, Cleeland, C.S, Fallowfield, L.J, Patrick, D.L, Fizazi, K, Smith, M.R, Maroto, J.P, Michel, M.S, Feng, A, Goessl, C, Chung, K

Get full text

1763P Real-world outcomes before and after the access to immune-checkpoint inhibitors (ICI) in advanced urothelial carcinoma (aUC) by Tapia, J.C., Anguera Palacios, G., Gavira, J., Bosma, F., Sanchez Del Rio, S., Sanz Beltran, J., Molina Pérez, M.A., Aguado Sorolla, M., Piedra, A., Maroto Rey, J.P.

Get full text

1450MO Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC by Grimm, M-O., Esteban Gonzalez, E., Barthelemy, P., Schmidinger, M., Busch, J., Perez Valderrama, B., Charnley, N., Schmitz, M., Schumacher, U., Baretton, G., Duran Martinez, I., De Velasco Oria, G.A., Priou, F., Maroto Rey, J.P., Albiges, L.

Get full text

1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC) by Voss, M.H., Garmezy, B., Kim, S.H., Maroto Rey, J.P., Mansinho, A.B., Rodriguez-Vida, A., Oliveira, J., van Dongen, M., Rodríguez, L. Medina, Negrier, S., Tran, B., Carneiro, B.A., Alvarez, E. Castanon, Rha, S.Y., Wang, Y., Gainer, S.D., Tang, Z., Achour, I., Asare, J.M., Albiges, L.

Get full text

631P Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration resistant prostate cancer in an open-label phase Ib study by Rodriguez-Vida, A., Maroto Rey, J.P., Font Pous, A., Martin, C., Mellado, B., Corbera Lloret, A., Orrillo Sarmiento, M., Reig Torras, O., Querol Ninerola, R., Cano, L., Palazon, A., Alonso, J., Galtes, S., Juanpere, N., Juan, O., Bellmunt, J.

Get full text

695TiP ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to characterize the prostate cancer pathway, management and outcomes in Europe, Middle East and Africa (EMEA region) by Carles, J., Alcaraz, A., Clarke, N.W., Conde, A., Heidenreich, A., Juarez, A., Maroto Rey, J.P., Puente, J., Hernandez-Medrano, I., Salcedo, I., Haddad, I., Munoz del Toro, J., Servan, A., Pissart, G., Casariego, J., Fizazi, K.

Get full text

SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials by Arranz Arija, J., Pérez Valderrama, B., Rodríguez Sánchez, Á., Chirivella González, I., Anido Herranz, U., Maroto Rey, J.P., Miranda Pallares, M.J., Climent Duran, M.A., Crespo Herrero, G., Meana Garcia, J.A., Rodriguez-Vida, A., Fernandez-Rodriguez, R., Santander, C., Rubio Romero, G., Vazquez Estevez, S., Fernandez Calvo, O., Gonzalez Gragera, M.B., Almagro Casado, E., Perez Ramirez, S., Borrega García, P.

Get full text